Cancer immunotherapy successes and failures with very good examples: Dendreon and Juno Therapeutics
What scientific, legal, and business challenges does the immunotherapy companies face? Stewart Lyman looks at some of them: intellectual property concerns, technology issues, huge manufacturing costs, pressures on pricing and reimbursement, obsolescence and limited patient populations. Find out more
